Today: 10 June 2026
Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher
23 January 2026
1 min read

Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher

Mumbai, Jan 23, 2026, 16:14 IST

Atul Ltd shares finished roughly 1% up on Friday following a strong quarterly profit report from the Indian speciality chemicals company. The stock closed at 5,833.25 rupees, marking a 1.03% gain.

As India’s December-quarter earnings season unfolds, investors are sorting out signal from noise. In chemicals, even a slight move in costs or pricing quickly impacts margins.

Labour costs have added a new wrinkle. Firms are now wrestling with how India’s new labour codes affect the accounting of certain employee benefit expenses.

Indian stocks closed lower, the Nifty 50 slipping 0.95% to 25,048.65.

Atul reported a consolidated net profit of 163.54 crore rupees for the October-December quarter, the third in its 2025-26 fiscal year ending March. Revenue for the period reached 1,573.62 crore, marking an 11% rise from a year ago, while profit jumped nearly 40%. However, profit slipped compared to the previous quarter despite a slight increase in sales. Revenue from life science chemicals fell marginally, whereas performance and other chemicals saw growth. The company also noted a 36.61 crore rupee provision in its standalone accounts related to the new labour codes.

Costs kept climbing. Operating expenses increased 2.9% from the previous quarter, reaching 1,410.06 crore rupees. Employee benefit expenses surged to 166.73 crore, which included a 41.35 crore rupee provision tied to labour code changes. For the nine months ending Dec. 31, revenue grew 11.4% to 4,603.47 crore, while profit rose to 478.27 crore, the report noted.

Atul reported EBITDA of roughly 248 crore rupees, with its margin slipping slightly to 15.7% from 15.8% the previous year, ET Now said.

Sunil Lalbhai serves as the chairman of the company. Its publicly traded competitors in India’s speciality chemicals sector include Navin Fluorine International, Deepak Nitrite, and Vinati Organics, based on market data services.

The key variable remains whether labour-code related provisioning and employee expenses stay high — and if demand remains strong enough for producers to maintain price hikes. Should costs remain elevated while pricing falters, earnings could drop sharply, even if sales stay steady.

Stock Market Today

  • Masimo Corp to Delist from Nasdaq as Per SEC Form 25 Filing
    June 10, 2026, 10:17 AM EDT. Masimo Corp has filed SEC Form 25 to delist its common stock from the Nasdaq Stock Market, signaling removal of its securities from exchange listing and registration. The move, filed under the Securities Exchange Act of 1934, was submitted by Nasdaq on June 10, 2026, and reflects compliance with regulatory requirements for delisting. The filing was certified by Nasdaq's AVP Tara Petta. This action typically indicates strategic changes by the company or voluntary deregistration, affecting investors as the stock will no longer be traded on Nasdaq.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Previous Story

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
Next Story

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

Go toTop